{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:05:24Z","timestamp":1784905524525,"version":"3.55.0"},"reference-count":58,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Pompe disease is a lysosomal storage disorder caused by autosomal recessive mutations in the acid alpha-glucosidase (GAA) gene. Acid alpha-glucosidase deficiency leads to abnormal glycogen accumulation in patient cells. Given the increasing evidence of central nervous system (CNS) involvement in classic infantile Pompe disease, we used neural stem cells, differentiated from patient induced pluripotent stem cells, to model the neuronal phenotype of Pompe disease. These Pompe neural stem cells exhibited disease-related phenotypes including glycogen accumulation, increased lysosomal staining, and secondary lipid buildup. These morphological phenotypes in patient neural stem cells provided a tool for drug efficacy evaluation. Two potential therapeutic agents, hydroxypropyl-\u03b2-cyclodextrin and \u03b4-tocopherol, were tested along with recombinant human acid alpha-glucosidase (rhGAA) in this cell-based Pompe model. Treatment with rhGAA reduced LysoTracker staining in Pompe neural stem cells, indicating reduced lysosome size. Additionally, treatment of diseased neural stem cells with the combination of hydroxypropyl-\u03b2-cyclodextrin and \u03b4-tocopherol significantly reduced the disease phenotypes. These results demonstrated patient-derived Pompe neural stem cells could be used as a model to study disease pathogenesis, to evaluate drug efficacy, and to screen compounds for drug discovery in the context of correcting CNS defects.<\/jats:p>","DOI":"10.3390\/cells10010008","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T12:42:28Z","timestamp":1608640948000},"page":"8","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Modeling CNS Involvement in Pompe Disease Using Neural Stem Cells Generated from Patient-Derived Induced Pluripotent Stem Cells"],"prefix":"10.3390","volume":"10","author":[{"given":"Yu-Shan","family":"Cheng","sequence":"first","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-1962","authenticated-orcid":false,"given":"Shu","family":"Yang","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hong","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Beers","sequence":"additional","affiliation":[{"name":"iPSC Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhong","family":"Zou","sequence":"additional","affiliation":[{"name":"iPSC Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Huang","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1034-0757","authenticated-orcid":false,"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"Reuser","year":"2008","journal-title":"Lancet"},{"key":"ref_2","unstructured":"Valle, D.L., Antonarakis, S., Ballabio, A., Beaudet, A.L., and Mitchell, G.A. (2019). Pompe Disease: Glycogen Storage Disease Type II, Acid \u03b1-Glucosidase (Acid Maltase) Deficiency. The Online Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Education."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1152\/physiolgenomics.00075.2016","article-title":"Transcriptome assessment of the Pompe (Gaa-\/-) mouse spinal cord indicates widespread neuropathology","volume":"48","author":"Turner","year":"2016","journal-title":"Physiol. Genom."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/hmg\/ddu476","article-title":"Peripheral nerve and neuromuscular junction pathology in Pompe disease","volume":"24","author":"Falk","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: From bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","article-title":"The respiratory neuromuscular system in Pompe disease","volume":"189","author":"Fuller","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ebbink, B.J., Poelman, E., Aarsen, F.K., Plug, I., R\u00e9gal, L., Muentjes, C., van der Beek, N., Lequin, M.H., van der Ploeg, A.T., and van den Hout, J.M. (2018). Classic infantile Pompe patients approaching adulthood: A cohort study on consequences for the brain. Dev. Med. Child Neurol., 60.","DOI":"10.1111\/dmcn.13740"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1093\/hmg\/ddr424","article-title":"Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification","volume":"20","author":"Huang","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15023","DOI":"10.1038\/mtm.2015.23","article-title":"Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient","volume":"2","author":"Sato","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1074\/jbc.M114.628628","article-title":"Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes","volume":"290","author":"Raval","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5966\/sctm.2015-0409","article-title":"Metabolomic Profiling of Pompe Disease-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated with Cardiac and Skeletal Muscle Pathology","volume":"6","author":"Sato","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16054","DOI":"10.1038\/mtm.2016.54","article-title":"TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle","volume":"3","author":"Sato","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.omtn.2017.03.002","article-title":"GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells","volume":"7","author":"Bergsma","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13473","DOI":"10.1038\/s41598-017-14063-y","article-title":"A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells","volume":"7","author":"Yoshida","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13023-017-0670-9","article-title":"Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics","volume":"12","author":"Aguisanda","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sima, N., Li, R., Huang, W., Xu, M., Beers, J., Zou, J., Titus, S., Ottinger, E.A., Marugan, J.J., and Xie, X. (2018). Neural Stem Cells for Disease Modeling and Evaluation of Therapeutics for Infantile (CLN1\/PPT1) and Late Infantile (CLN2\/TPP1) Neuronal Ceroid Lipofuscinoses. Orphanet J. Rare Dis., 13.","DOI":"10.1186\/s13023-018-0798-2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39349","DOI":"10.1074\/jbc.M112.357707","article-title":"\u03b4-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders*","volume":"287","author":"Xu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/1087057114537378","article-title":"Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy","volume":"19","author":"Yu","year":"2014","journal-title":"J. Biomol. Screen."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.5966\/sctm.2015-0373","article-title":"Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A","volume":"5","author":"Long","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chen, F.W., Li, C., and Ioannou, Y.A. (2010). Cyclodextrin induces calcium-dependent lysosomal exocytosis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015054"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11319","DOI":"10.1038\/srep11319","article-title":"A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture","volume":"5","author":"Beers","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/nprot.2012.130","article-title":"Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions","volume":"7","author":"Beers","year":"2012","journal-title":"Nat. Protoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.gim.0000217781.66786.9b","article-title":"Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease","volume":"8","author":"Zhang","year":"2006","journal-title":"Genet. Med."},{"key":"ref_27","unstructured":"NHLBI GO Exome Sequencing Project (ESP) (2020, February 20). Exome Variant Server. Available online: http:\/\/evs.gs.washington.edu\/EVS\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101435","DOI":"10.1016\/j.scr.2019.101435","article-title":"A human induced pluripotent stem cell line (TRNDi007-B) from an infantile onset Pompe patient carrying p.R854X mutation in the GAA gene","volume":"37","author":"Cheng","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13023-018-0886-3","article-title":"Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease","volume":"13","author":"Vu","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2013.08.010","article-title":"A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease","volume":"111","author":"Wang","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_31","first-page":"73","article-title":"Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA","volume":"47","author":"Martiniuk","year":"1990","journal-title":"Am. J. Hum. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1087057113501197","article-title":"A phenotypic compound screening assay for lysosomal storage diseases","volume":"19","author":"Xu","year":"2014","journal-title":"J. Biomol. Screen."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mus.880140509","article-title":"Infantile Pompe\u2019s disease, lipid storage, and partial carnitine deficiency","volume":"14","author":"Verity","year":"1991","journal-title":"Muscle Nerve"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/archneur.1982.00510150050012","article-title":"Lipid storage myopathy in infantile Pompe\u2019s disease","volume":"39","author":"Sarnat","year":"1982","journal-title":"Arch. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gorba, T., and Conti, L. (2013). Neural Stem Cells as Tools for Drug Discovery: Novel Platforms and Approaches. Expert Opin. Drug Discov., 8.","DOI":"10.1517\/17460441.2013.805199"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1242\/dmm.029009","article-title":"Induced pluripotent stem cell models of lysosomal storage disorders","volume":"10","author":"Borger","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00441-017-2713-x","article-title":"Modeling neurological diseases using iPSC-derived neural cells","volume":"371","author":"Li","year":"2017","journal-title":"Cell Tissue Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Swaroop, M., Brooks, M.J., Gieser, L., Swaroop, A., and Zheng, W. (2018). Patient iPSC-derived Neural Stem Cells Exhibit Phenotypes in Concordance With the Clinical Severity of Mucopolysaccharidosis I. Hum. Mol. Genet., 27.","DOI":"10.1093\/hmg\/ddy259"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/clc.22422","article-title":"Tocopherols in the Prevention and Treatment of Atherosclerosis and Related Cardiovascular Disease","volume":"38","author":"Mathur","year":"2015","journal-title":"Clin. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1940-6207.CAPR-12-0263","article-title":"Dietary Administration of \u03b4- and \u03b3-Tocopherol Inhibits Tumorigenesis in the Animal Model of Estrogen Receptor-Positive, but not HER-2 Breast Cancer","volume":"5","author":"Smolarek","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1940-6207.CAPR-11-0521","article-title":"\u03b4- and \u03b3-tocopherols, but not \u03b1-tocopherol, inhibit colon carcinogenesis in azoxymethane-treated F344 rats","volume":"5","author":"Guan","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1940-6207.CAPR-10-0130","article-title":"\u03b4-tocopherol is more active than \u03b1- or \u03b3-tocopherol in inhibiting lung tumorigenesis In Vivo","volume":"4","author":"Li","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/mc.22422","article-title":"\u03b4-Tocopherol inhibits receptor tyrosine kinase-induced AKT activation in prostate cancer cells","volume":"55","author":"Wang","year":"2015","journal-title":"Mol. Carcinog."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"276ra26","DOI":"10.1126\/scitranslmed.3010101","article-title":"Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease","volume":"7","author":"Vite","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ymgme.2016.04.014","article-title":"In vitro evaluation of 2-hydroxyalkylated \u03b2-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease","volume":"118","author":"Kondo","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Davidson, C.D., Ali, N.F., Micsenyi, M.C., Stephney, G., Renault, S., Dobrenis, K., Ory, D.S., Vanier, M.T., and Walkley, S.U. (2009). Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006951"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1073\/pnas.0810895106","article-title":"Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-\/- mouse","volume":"106","author":"Liu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0024-3205(01)01384-4","article-title":"Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease","volume":"70","author":"Camargo","year":"2001","journal-title":"Life Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"Barohn","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/8904_2014_392","article-title":"Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany","volume":"20","author":"Hahn","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: A systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"key":"ref_55","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","article-title":"Deconstructing Pompe disease by analyzing single muscle fibers: To see a world in a grain of sand","volume":"3","author":"Raben","year":"2007","journal-title":"Autophagy"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Do, H.V., Raben, N., Khanna, R., Xu, S., Lun, Y., Frascella, M., Garcia, A., Soska, R., Nair, A., and Ponery, A.S. (2019). Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight, 4.","DOI":"10.1172\/jci.insight.125358"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Huang, H.P., Chiang, W., Stone, L., Kang, C.K., Chuang, C.Y., and Kuo, H.C. (2019). Using human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential. Hum. Mol. Genet.","DOI":"10.1093\/hmg\/ddz218"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/1\/8\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:31Z","timestamp":1760179711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/1\/8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["cells10010008"],"URL":"https:\/\/doi.org\/10.3390\/cells10010008","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]}}}